OBJECTIVE: To evaluate the diagnostic potential of a multi-factor analysis of morphometric parameters and signal characteristics of brain tumours and peritumoural areas for distinguishing WHO-grade II and III gliomas at magnetic resonance imaging (MRI). METHODS: MR examinations of 108 patients with histologically proven World Health Organization (WHO) grade II and III gliomas were included. Morphological criteria and MR signal characteristics were evaluated. The data were subjected to a multifactorial logistic regression analysis to differentiate between grade II and grade III gliomas. The discriminatory power was assessed by receiver operating characteristic (ROC). RESULTS: Logistic regression analysis showed that WHO grade II and III can be distinguished based on contrast enhancement, cortical involvement, margin of the enhancing lesion and maximum diameter (width and length) of the peritumoural area (the so-called tumour infiltration zone). With the final model of logistic regression analysis and with the cut-off value ≥ 0.377, WHO grade III glioma is predicted with a sensitivity of 71.0 % and a specificity of 80.4 %. CONCLUSION: Measurement of maximum diameter of peritumoural area, contrast enhancement as well as cortical involvement and the margin of the contrast-enhancing lesion can be used easily in clinical routine to adequately distinguish WHO grade II from grade III gliomas. KEY POINTS: • MRI offers new information concerning WHO-grade II and III gliomas. • The differentiation between such tumour grades is important for therapeutic decisions. • We assessed differences in enhancement, cortical involvement, margins and peritumoural appearances. • WHO grade III gliomas can be predicted with reasonable sensitivity and specificity.
OBJECTIVE: To evaluate the diagnostic potential of a multi-factor analysis of morphometric parameters and signal characteristics of brain tumours and peritumoural areas for distinguishing WHO-grade II and III gliomas at magnetic resonance imaging (MRI). METHODS: MR examinations of 108 patients with histologically proven World Health Organization (WHO) grade II and III gliomas were included. Morphological criteria and MR signal characteristics were evaluated. The data were subjected to a multifactorial logistic regression analysis to differentiate between grade II and grade III gliomas. The discriminatory power was assessed by receiver operating characteristic (ROC). RESULTS: Logistic regression analysis showed that WHO grade II and III can be distinguished based on contrast enhancement, cortical involvement, margin of the enhancing lesion and maximum diameter (width and length) of the peritumoural area (the so-called tumour infiltration zone). With the final model of logistic regression analysis and with the cut-off value ≥ 0.377, WHO grade III glioma is predicted with a sensitivity of 71.0 % and a specificity of 80.4 %. CONCLUSION: Measurement of maximum diameter of peritumoural area, contrast enhancement as well as cortical involvement and the margin of the contrast-enhancing lesion can be used easily in clinical routine to adequately distinguish WHO grade II from grade III gliomas. KEY POINTS: • MRI offers new information concerning WHO-grade II and III gliomas. • The differentiation between such tumour grades is important for therapeutic decisions. • We assessed differences in enhancement, cortical involvement, margins and peritumoural appearances. • WHO grade III gliomas can be predicted with reasonable sensitivity and specificity.
Authors: Nathalie L Jansen; Vera Graute; Lena Armbruster; Bogdana Suchorska; Juergen Lutz; Sabina Eigenbrod; Paul Cumming; Peter Bartenstein; Jörg-Christian Tonn; Friedrich Wilhelm Kreth; Christian la Fougère Journal: Eur J Nucl Med Mol Imaging Date: 2012-04-11 Impact factor: 9.236
Authors: A Brunetti; B Alfano; A Soricelli; E Tedeschi; C Mainolfi; E M Covelli; L Aloj; M R Panico; L Bazzicalupo; M Salvatore Journal: Nucl Med Biol Date: 1996-08 Impact factor: 2.408
Authors: R Ashok Kumar; Niranjan Khandelwal; Kushaljit Singh Sodhi; A Pathak; B R Mittal; B D Radotra; Sudha Suri Journal: J Comput Assist Tomogr Date: 2006 Sep-Oct Impact factor: 1.826
Authors: Tracy R McKnight; Kathleen R Lamborn; Tonya D Love; Mitchel S Berger; Susan Chang; William P Dillon; Andrew Bollen; Sarah J Nelson Journal: J Neurosurg Date: 2007-04 Impact factor: 5.115
Authors: Anna F Delgado; Markus Fahlström; Markus Nilsson; Shala G Berntsson; Maria Zetterling; Sylwia Libard; Irina Alafuzoff; Danielle van Westen; Jimmy Lätt; Anja Smits; Elna-Marie Larsson Journal: Radiol Oncol Date: 2017-02-15 Impact factor: 2.991
Authors: Anna F Delgado; Markus Nilsson; Francesco Latini; Johanna Mårtensson; Maria Zetterling; Shala G Berntsson; Irina Alafuzoff; Jimmy Lätt; Elna-Marie Larsson Journal: Radiol Res Pract Date: 2016-04-17
Authors: Arthur Hosmann; Matthias Millesi; Lisa I Wadiura; Barbara Kiesel; Petra A Mercea; Mario Mischkulnig; Martin Borkovec; Julia Furtner; Thomas Roetzer; Stefan Wolfsberger; Joanna J Phillips; Anna S Berghoff; Shawn Hervey-Jumper; Mitchel S Berger; Georg Widhalm Journal: Cancers (Basel) Date: 2021-05-21 Impact factor: 6.575